The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for lanadelumab (Takeda Pharmaceuticals Australia Pty Ltd)
Active ingredients
lanadelumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Solution for injection
Indication
Lanadelumab is indicated for the routine prevention of angioedema attacks and control of symptoms of HAE in paediatric patients 2 to <12 years
Therapeutic area
Immunology